Cancer Immunotherapies: Are They as Effective in the Elderly?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Drugs & Aging

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40266-017-0479-1PMID 28707274
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  2017cited by this paper
• Immune checkpoint inhibitors in challenging populations

  2017cited by this paper
• Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

  2017cited by this paper
• FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

  2017cited by this paper
• Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

  2017cited by this paper
• U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

  2017cited by this paper
• Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

  2017cited by this paper
• Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

  2017cited by this paper
• Association of PD‐1, PD‐L1, and CTLA‐4 Gene Expression and Clinicopathologic Characteristics in Patients With Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types.

  2017cited by this paper
• Approvals in 2016: the march of the checkpoint inhibitors

  2017cited by this paper
• Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.

  2017cited by this paper
• Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

  2017cited by this paper
• Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma

  2017cited by this paper
• Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

  2017cited by this paper
• Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

  2017cited by this paper
• Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

  2017cited by this paper
• CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.

  2017cited by this paper
• Considerations for successful cancer immunotherapy in aged hosts

  2017cited by this paper
• Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

  2016cited by this paper
• Follicular Lymphoma: The Management of Elderly Patient

  2016cited by this paper
• Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

  2016cited by this paper
• Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

  2016cited by this paper
• Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

  2016cited by this paper
• Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

  2016cited by this paper
• Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

  2016cited by this paper
• Nivolumab for recurrent squamous-cell carcinoma of the head and neck

  2016cited by this paper
• The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis

  2016cited by this paper
• PS01.53: First‐Line Atezolizumab Plus Chemotherapy in Chemotherapy‐Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology

  2016cited by this paper
• Responses to immune checkpoint inhibitors in nonagenarians

  2016cited by this paper
• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

  2016cited by this paper
• Direct measurement of T cell receptor affinity and sequence from naïve antiviral T cells

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.

  2016cited by this paper
• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

  2016cited by this paper
• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts

  2016cited by this paper
• Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study

  2016cited by this paper
• Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?

  2016cited by this paper
• Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma

  2016cited by this paper
• FDA approvals for the first 6 months of 2016

  2016cited by this paper
• Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

  2016cited by this paper
• A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B‐cell lymphoma

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.

  2016cited by this paper
• Pembrolizumab for the treatment of non-small cell lung cancer

  2016cited by this paper
• Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

  2015cited by this paper
• Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Abstract 4055: Immune checkpoint protein expression is up-regulated in tumor-bearing elderly mice

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• FDA approvals for the first 6 months of 2015

  2015cited by this paper
• Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.

  2015cited by this paper
• Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• GSTM1 null genotype may be associated with an increased nasopharyngeal cancer risk in South China: an updated meta-analysis and review

  2015cited by this paper
• Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: data from PROCEED.

  2014cited by this paper
• Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

  2014cited by this paper
• Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL.

  2014cited by this paper
• Cancer Immunology at the Crossroads : Experimental Immunotherapies Oncolytic Viruses and Their Application to Cancer Immunotherapy

  2014cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

  2014cited by this paper
• Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

  2014cited by this paper
• Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?

  2014influential reference
• Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

  2013cited by this paper
• Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer

  2013cited by this paper
• Human T Cell Aging and the Impact of Persistent Viral Infections

  2013cited by this paper
• Optimization of immunotherapy in elderly cancer patients.

  2013cited by this paper
• Targeting macrophages rescues age‐related immune deficiencies in C57BL/6J geriatric mice

  2013cited by this paper
• A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer

  2013cited by this paper
• Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy

  2013influential reference
• Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

  2013cited by this paper
• Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.

  2013cited by this paper
• Mechanisms of action of CD20 antibodies.

  2012cited by this paper
• Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.

  2012cited by this paper
• Mechanisms of action of CD 20 antibodies

  2012cited by this paper
• Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.

  2012cited by this paper
• An Italian retrospective study on the routine clinical use of low‐dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

  2012cited by this paper
• Aging, immunity, and cancer.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

  2011cited by this paper
• Immunity, cancer and aging: lessons from mouse models.

  2011cited by this paper
• Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

  2011cited by this paper
• A Role for Immature Myeloid Cells in Immune Senescence

  2011cited by this paper
• Age-related changes in plasma levels of inflamatory and angiogenic cytokins in patients with cancer.

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

  2010cited by this paper
• Cancer vaccination: manipulation of immune responses at old age.

  2009cited by this paper
• Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

  2009cited by this paper
• OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases with Age

  2009cited by this paper
• Inflammation, ageing and cancer.

  2009cited by this paper
• Functional Regulatory T Cells Accumulate in Aged Hosts and Promote Chronic Infectious Disease Reactivation1

  2008cited by this paper

• Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

  2025cites this paper
• A review of current and emerging therapies in breast cancer: implications for older adults

  2025cites this paper
• Veränderungen des Immunsystems im Alter: Immunseneszenz und Auswirkungen auf Impfungen

  2025cites this paper
• Tumor immunology: unraveling the complex interaction between tumors and the immune system: a narrative review

  2025cites this paper
• Clinical outcomes, toxic effect, and immune microenvironment changes of drug-eluting bead bronchial arterial chemoembolisation/bronchial arterial chemoembolization combined with immunotherapy in treating elderly patients with non-small cell lung cancer.

  2025cites this paper
• Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer

  2024cites this paper
• Endometrial cancer in the elderly: characteristics, prognostic and risk factors, and treatment options.

  2024cites this paper
• Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology.

  2024cites this paper
• Identification of cellular senescence-associated genes as new biomarkers for predicting the prognosis and immunotherapy response of non-small cell lung cancer and construction of a prognostic model

  2024cites this paper
• Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study

  2023cites this paper
• Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma

  2023cites this paper
• A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer

  2023cites this paper
• Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre

  2023cites this paper
• Immunotherapy for older patients with cancer.

  2023cites this paper
• Nutrition Interventions of Herbal Compounds on Cellular Senescence

  2022cites this paper
• Early distinction of lymph node metastasis in patients with soft tissue sarcoma and individualized survival prediction using the online available nomograms: A population-based analysis

  2022cites this paper
• Construction of Molecular Subtype and Prognosis Prediction Model of Osteosarcoma Based on Aging-Related Genes

  2022cites this paper
• Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper.

  2022cites this paper
• Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy

  2021cites this paper
• Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study

  2021cites this paper
• The effects of age and systemic metabolism on anti-tumor T cell responses

  2020cites this paper
• Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8+ T cells in early clinical stages of chronic lymphocytic leukemia

  2020cites this paper
• Impact of age on the toxicity of immune checkpoint inhibition

  2020cites this paper
• Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)

  2020cites this paper
• Comprehensive geriatric assessment in older adults with cancer: Recommendations by the Italian Society of Geriatrics and Gerontology (SIGG)

  2020cites this paper
• Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer

  2020cites this paper
• Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders.

  2020cites this paper
• Effectiveness of Multi-Prognostic Index in older patients with advanced malignancies treated with immunotherapy.

  2020cites this paper
• The ageing immune system: Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity?

  2019cites this paper
• Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

  2019cites this paper
• The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.

  2019cites this paper
• Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age

  2019cites this paper
• Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.

  2019cites this paper
• Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity?

  2019cites this paper
• Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.

  2019cites this paper
• Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents

  2018cites this paper
• Treatment of Elderly Patients with Head and Neck Cancer

  2018cites this paper
• [An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function].

  2018cites this paper
• Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma

  2018cites this paper
• Immunotherapy in the Elderly.

  2017cites this paper